300 years of Andrew Witty? What to buy with $3 billion
This article was originally published in Scrip
GlaxoSmithKline, part of what used to be called 'the ethical pharmaceutical industry' back in the days when Boy Scouts wore short pants, was docked a record $3 billion in state and federal fines and in liabilities in the US for misdemeanours violations concerning the marketing of antidepressants and its diabetes drug, Avandia (scripintelligence.com, 3 July 2012).
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.